A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to generate defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, exactly when they are highly susceptible to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence suggesting that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent protection when immunised 4 weeks before birth
- Maternal antibodies transferred through the placenta safeguard newborns from day one
- Protection achievable with 2-week gap before early delivery
- Vaccination during the third trimester still offers significant infant protection
Strong evidence from recent research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a thorough investigation conducted across England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month period, providing comprehensive and reliable data of the vaccine’s practical effectiveness. The study’s results have been validated by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scope of this study provides healthcare professionals and expectant parents with trust in the vaccine’s proven efficacy across different groups and contexts.
The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the vast majority being infants whose mothers had not received the vaccination. This stark contrast emphasises the vaccine’s critical role in preventing serious illness in newborns. The drop in hospital admissions above 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology assessed real-world outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine functions when delivered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection triggers deep inflammation in the lungs and airways, making it perilously hard for affected infants to breathe and feed effectively. Parents often witness their babies fighting for breath, their chests rising whilst they try to pull sufficient oxygen into their damaged lungs. Whilst most infants improve through supportive care, a small but significant number die from RSV-related complications annually, making prevention through vaccination a vital health service objective for safeguarding the youngest and most at-risk members of society.
- RSV triggers inflammation in lungs, leading to severe breathing difficulties in babies
- Half of all infants catch the virus during their first few months alive
- Symptoms range from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- A small number of infants succumb to RSV related complications annually in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have emphasised the value of pregnant women receiving their jab at the optimal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers nearly 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies through the placenta.
The messaging from public health bodies remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong protection for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These geographical variations reflect differences across medical facilities, engagement approaches, and local engagement efforts, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to reach women during pregnancy
- Regional disparities in vaccination coverage levels in different parts of England require targeted improvement
- Local healthcare systems adapting programmes to align with community needs and circumstances
Practical implications and parental perspectives
The vaccine’s outstanding effectiveness translates into tangible benefits for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the rollout of this safeguarding intervention, the 80% decrease in admissions means thousands of infants protected against serious illness. Parents no more face the distressing scenario of seeing their babies labour to breathe or difficulty feeding, symptoms that mark critical RSV illness. The vaccine has markedly changed the landscape of neonatal lung health, providing expectant mothers a preventative option to protect their youngest infants during those vital initial period.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s promotion of the jab underscores the profound consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to pregnant women in their third trimester, transforming what was once an inevitable seasonal threat into a manageable risk.